Rani Therapeutics Holdings, Inc.
RANI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,028 | $0 | $0 | $2,717 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $822 | $0 | $0 |
| Gross Profit | $1,028 | -$822 | $0 | $2,717 |
| % Margin | 100% | – | – | 100% |
| R&D Expenses | $26,682 | $39,624 | $36,607 | $26,482 |
| G&A Expenses | $23,946 | $26,475 | $26,844 | $27,834 |
| SG&A Expenses | $23,946 | $26,475 | $26,844 | $27,834 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3,714 | -$822 | $0 | $0 |
| Operating Expenses | $54,342 | $65,277 | $63,451 | $54,316 |
| Operating Income | -$53,314 | -$66,099 | -$63,451 | -$51,599 |
| % Margin | -5,186.2% | – | – | -1,899.1% |
| Other Income/Exp. Net | $23,296 | -$1,784 | $177 | -$1,448 |
| Pre-Tax Income | -$30,018 | -$67,883 | -$63,274 | -$53,047 |
| Tax Expense | $26,566 | $0 | $70 | $41 |
| Net Income | -$30,018 | -$33,970 | -$30,588 | -$8,331 |
| % Margin | -2,920% | – | – | -306.6% |
| EPS | -1.05 | -1.33 | -1.28 | -0.42 |
| % Growth | 21.1% | -3.9% | -204.8% | – |
| EPS Diluted | -1.05 | -1.33 | -1.28 | -0.42 |
| Weighted Avg Shares Out | 28,476 | 25,505 | 23,817 | 19,534 |
| Weighted Avg Shares Out Dil | 28,476 | 25,505 | 23,817 | 19,534 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,763 | $3,301 | $1,248 | $89 |
| Interest Expense | $5,033 | $5,085 | $1,071 | $466 |
| Depreciation & Amortization | $1,028 | $822 | $548 | $497 |
| EBITDA | -$50,523 | -$65,277 | -$61,655 | -$52,084 |
| % Margin | -4,914.7% | – | – | -1,917% |